Search Results - Vivek Subbiah

Refine Results
  1. 1

    Tissue is Still the Issue for Precision Oncology: A Novel Web-Based Platform for Lesion Selection and Biopsy Specimen Acquisition by Vivek Subbiah

    Get full text
    Article


  2. 2

    Tissue-agnostic cancer therapies: promise, reality, and the path forward by Vivek Subbiah

    Published in Nature Communications (2025-05-01)
    Get full text
    Article


  3. 3

    COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining by Aakash Desai, Vivek Subbiah

    Get full text
    Article


  4. 4

    Precision oncology with selective RET inhibitor selpercatinib in -rearranged cancers by Mohamed A. Gouda, Vivek Subbiah

    Published in Therapeutic Advances in Medical Oncology (2023-06-01)
    Get full text
    Article


  5. 5

    Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis by Kalevi Kairemo, Homer A. Macapinlac, Mohammed Gouda, Vivek Subbiah

    Published in Diagnostics (2024-08-01)
    Get full text
    Article


  6. 6

    Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma by Albert Grinshpun, Yonaton Zarbiv, Jason Roszik, Vivek Subbiah, Ayala Hubert

    Published in Case Reports in Oncology (2019-01-01)
    Get full text
    Article


  7. 7

    Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT in Lung Cancer by Kalevi Kairemo, Elmer B. Santos, Homer A. Macapinlac, Vivek Subbiah

    Published in Diagnostics (2020-01-01)
    Get full text
    Article


  8. 8

    For what it’s worth: the complex area of medicine value assessment by Sreeram V Ramagopalan, Catrin Treharne, Jonathan Pearson-Stuttard, Vivek Subbiah

    Article


  9. 9

    On target methods to induce abscopal phenomenon for Off‐Target effects: From happenstance to happenings by Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

    Published in Cancer Medicine (2023-03-01)
    Get full text
    Article


  10. 10

    Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer by Edwin Lin, Ying-Chun Lo, Vivek Subbiah, Rajat Thawani, Aakash Desai

    Published in Experimental Hematology & Oncology (2025-07-01)
    Get full text
    Article


  11. 11

    Development of anti-cancer medicines in the current era by Bradley J. Monk, Manish R. Patel, Sarper Toker, Vivek Subbiah, Lucio N. Gordan

    Get full text
    Article


  12. 12

    The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy by Sreeram Ramagopalan, Thomas P. Leahy, Joshua Ray, Samantha Wilkinson, Cormac Sammon, Vivek Subbiah

    Published in BMC Medicine (2021-09-01)
    Get full text
    Article


  13. 13

    The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib by Tao Shen, Xueqing Hu, Xuan Liu, Vivek Subbiah, Blaine H. M. Mooers, Jie Wu

    Published in npj Precision Oncology (2021-06-01)
    Get full text
    Article


  14. 14

    Drugging KRAS: current perspectives and state-of-art review by Kaushal Parikh, Giuseppe Banna, Stephen V. Liu, Alex Friedlaender, Aakash Desai, Vivek Subbiah, Alfredo Addeo

    Published in Journal of Hematology & Oncology (2022-10-01)
    Get full text
    Article


  15. 15

    Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers by Kristian Thorlund, Stephen Duffield, Sanjay Popat, Sreeram Ramagopalan, Alind Gupta, Grace Hsu, Paul Arora, Vivek Subbiah

    Article


  16. 16

    Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study by Suzanne Murray, Vivek Subbiah, Steven I. Sherman, Sophie Péloquin, Anthony Sireci, Christian Grohé, Patrick Bubach, Patrice Lazure

    Published in Thyroid Research (2023-08-01)
    Get full text
    Article


  17. 17

    Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response by Hanna E. Persha, Shumei Kato, Pradip De, Jacob J. Adashek, Jason K. Sicklick, Vivek Subbiah, Razelle Kurzrock

    Published in Journal of Hematology & Oncology (2022-08-01)
    Get full text
    Article


  18. 18

    Molecular Imaging with 3′-deoxy-3′[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study by Kalevi Kairemo, Elmer B. Santos, Homer A. Macapinlac, Shreyaskumar Patel, Anthony P. Conley, David S. Hong, Vivek Subbiah

    Published in Diagnostics (2020-02-01)
    Get full text
    Article


  19. 19

    Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumo... by Vivek Subbiah, Robert E Brown, Yunyun Jiang, Jamie Buryanek, Andrea Hayes-Jordan, Razelle Kurzrock, Pete M Anderson

    Published in PLoS ONE (2013-01-01)
    Get full text
    Article


  20. 20

    Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial by Mirella Nardo, Camila Braganca Xavier, Bettzy Stephen, Jeffrey A. How, Justin Moyers, Vivek Subbiah, David S. Hong, Aung Naing

    Get full text
    Article


Search Tools: